Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i>.

Similarly, participants with pre- or post-HCT MRD at a level of 1 × 10 −6 or greater had improved OS when treated with gilteritinib (Data Supplement, Fig 4) although this did not reach statistical significance ( P = .0731).

also in 111,027 other papers